Insmed is transitioning from cash-burning biotech to a commercial respiratory growth story, powered by BRINSUPRI’s rapid launch and improving margins. The stock looks attractive on execution, but valuation already reflects meaningful success.
Investment thesis: Insmed (INSM) is moving from a cash-burning biotech into a commercial respiratory company with a rapidly scaling growth engine. Second-quarter 2026 revenue reached $425.5M, including $309.2M from BRINSUPRI and $116.3M from ARIKAYCE. Operating loss narrowed to $1.5M and net loss narrowed to $13.2M, a sharp improvement from the $163.6M net loss in the first quarter.
The strongest part of the thesis is BRINSUPRI's launch. The product added approximately 7,000 new patients in Q2, more than 6,300 prescribers had written at least one prescription by June 30, and 30% of writers had prescribed it to at least five patients. Management raised 2026 BRINSUPRI revenue guidance to $1.25B to $1.4B and lifted its global peak-sales estimate above $7B.
The opportunity is substantial, but the stock already prices in a meaningful portion of the success. Insmed has a $28.6B market capitalization, a 25.3x enterprise-value-to-revenue multiple, negative trailing EPS of $4.12, and 2025 free cash flow of negative $967.6M. The medium-term reward is attractive if BRINSUPRI sustains its launch curve and TPIP advances, but a moderate-risk investor should treat INSM as a growth-oriented position rather than a defensive healthcare holding.
Insmed is a commercial-stage biotechnology company founded in 1988 and headquartered in Bridgewater, New Jersey. It employs 1,664 people and operates across the United States, Europe, Japan, and other international markets. The business focuses on serious and rare respiratory diseases, with additional programs in inflammation, pulmonary hypertension, fibrosis, gene therapy, and protein engineering.
The company has two marketed products. BRINSUPRI, or brensocatib, is an oral DPP1 inhibitor for non-cystic fibrosis bronchiectasis. ARIKAYCE is an inhaled amikacin product for refractory Mycobacterium avium complex lung disease. The pipeline includes TPIP, INS1033, INS1148, INS1201, and INS1202. Insmed reports one operating segment, so product and geographic performance provide the clearest view of the business mix.
BRINSUPRI is now the primary growth segment. Q2 revenue of $309.2M increased 49% sequentially from Q1, after Q1 revenue had increased 44% sequentially from Q4 2025. The product generated $207.9M in Q1, so the launch is building on an expanding commercial base rather than a single unusually large order.
ARIKAYCE remains the stabilizing segment. Q2 revenue of $116.3M grew 8% from the prior-year quarter, while management reiterated 2026 revenue guidance of $450M to $470M. In Q1, U.S. ARIKAYCE revenue was $62.9M and international revenue was $35.2M. International revenue grew 23% year over year in that quarter, offsetting a 2% decline in the U.S.
The mix is shifting quickly toward BRINSUPRI. Total company revenue rose from $363.7M in 2024 to $606.4M in 2025, then reached $306.0M in Q1 2026 and $425.5M in Q2. That mix shift matters because management reported Q2 cost of product revenue at $67.2M, or 16% of revenue, compared with 26% in the prior-year quarter. BRINSUPRI is improving the gross-margin profile as it becomes a larger share of sales.
Get AI research on any stock
Instant reports, daily intelligence, and an AI analyst in your pocket.
BRINSUPRI is the central asset in the Insmed investment case. The U.S. approval arrived on August 12, 2025, followed by European Commission approval in November 2025 and U.K. authorization in February 2026. It is the first approved disease-specific therapy for non-cystic fibrosis bronchiectasis in the United States, giving Insmed a valuable first-mover position.
Commercial indicators are unusually strong for a new specialty product. Insmed reported approximately 7,000 Q2 new patient starts, 6,300 cumulative prescribers, and a rise in prescribers with at least five patients from 20% in March to 30% in June. Payer access was approximately 90%, with approval for most patients taking less than a week. These figures point to adoption across both new physicians and existing writers.
The 2025 10-K identifies 13 U.S. Orange Book patents for BRINSUPRI, with key expirations extending into 2035 to 2040. That protection supports the product's long commercial runway. The main risk is execution: the valuation assumes that diagnosis improves, physicians deepen prescribing, and gross-to-net remains manageable. Insmed guided to BRINSUPRI gross-to-net in the mid- to high-20s for 2026.
Insmed's innovation advantage rests on focused respiratory expertise and a portfolio that shares physician call points. BRINSUPRI and ARIKAYCE address different diseases, but both rely on specialist respiratory relationships. Management expects that overlap to help future launches in Japan and reduce the need to build entirely separate commercial infrastructure.
TPIP provides the most important pipeline differentiation. In a Phase IIb pulmonary arterial hypertension study, TPIP produced a placebo-adjusted 35% reduction in pulmonary vascular resistance, a 35.5-meter improvement in six-minute walk distance, and a 60% reduction in NT-proBNP after 16 weeks. In the 12-month open-label extension, patients recorded an approximately 55-meter improvement in six-minute walk distance and an approximately 60% reduction in NT-proBNP from the lead-in baseline.
The TPIP program also reported 91% treatment continuation at 12 months, a 15% treatment-emergent cough rate, and 65% of patients reaching refined low-risk status on the REVEAL Light 2.0 scale. Phase III studies are active in pulmonary hypertension associated with interstitial lung disease and pulmonary arterial hypertension, while studies in progressive pulmonary fibrosis and idiopathic pulmonary fibrosis are scheduled to begin in late 2026 and early 2027.
The operating model is becoming more efficient as BRINSUPRI scales. Q2 cost of product revenue was $67.2M on $425.5M of revenue, producing an 84.2% gross margin. Management attributed the improvement partly to BRINSUPRI's lower manufacturing cost relative to ARIKAYCE. That mix benefit gives Insmed room to fund commercial expansion while moving toward profitability.
Insmed is increasing spending in parallel with revenue growth. Combined research and development and SG&A expenses rose 38% year over year in Q2 as the company funded the U.S. BRINSUPRI launch, TPIP Phase III trials, branded advertising, and Japanese commercial infrastructure. The company also expects $50M of AstraZeneca-related regulatory and sales milestones during the second half of 2026.
Operational execution extends beyond manufacturing. Insmed is working with the European Multicenter Bronchiectasis Audit and Research Collaboration on a three-year, open-label study of up to 3,000 patients across six European countries. The company is also funding diagnosis initiatives aimed at patients with bronchiectasis and comorbid COPD or asthma. These programs support demand creation, although they also add to near-term spending.
The bronchiectasis market offers unusual whitespace. Insmed's investor materials estimate more than 1 million potential BRINSUPRI patients worldwide, with diagnosed bronchiectasis prevalence of 2.4 million in the U.S., 2.1 million in the EU5, and 0.8 million in Japan. The commercial opportunity depends on identifying patients with frequent exacerbations and moving treatment earlier in the disease course.
ARIKAYCE has a separate expansion path. Insmed's materials estimate total MAC lung disease prevalence at 95,000 to 115,000 patients in the U.S., 12,000 to 17,000 in the EU5, and 1,400 in Japan. The ENCORE Phase 3b study met its primary and multiplicity-controlled secondary culture-conversion endpoints, supporting a supplemental U.S. filing for newly diagnosed patients.
TPIP broadens the addressable market beyond the current products. Management raised the potential peak sales estimate for TPIP above $6B from above $2B after positive data in pulmonary hypertension and plans to pursue four indications. That estimate assumes clinical and regulatory success across all four programs, so it represents pipeline upside rather than current revenue.
Like what you're reading?
Get full access to AI-powered research reports, market analysis, and portfolio tools.
The core customer base consists of pulmonologists, specialty respiratory clinics, hospitals, payers, and patients with serious chronic lung disease. BRINSUPRI's early adoption provides a useful customer signal: more than 6,300 prescribers had written for the product by the end of June, and approximately 30% had reached at least five patients.
Patient persistence and payer access are especially important for a chronic oral therapy. Insmed said payer approval was approximately 90%, approval for most patients took less than a week, and compliance and continuation rates were tracking ahead of internal benchmarks. The company is also investing in physician education because improved diagnosis among COPD and asthma patients can expand the treated population.
ARIKAYCE customers are more concentrated in specialist treatment settings because refractory MAC requires complex multidrug management. The planned move into newly diagnosed MAC would expand the physician base and move ARIKAYCE earlier in the treatment pathway. That expansion would also let Insmed use existing respiratory relationships rather than build a separate commercial network.
BRINSUPRI currently has the clearest competitive position. It entered a non-cystic fibrosis bronchiectasis market without an approved disease-specific rival in the United States. The practical alternatives are supportive care, airway-clearance methods, and off-label treatment regimens. Future competition remains a risk if the commercial success attracts larger pharmaceutical developers.
ARIKAYCE competes within a more established treatment ecosystem that includes multidrug background regimens and other inhaled or systemic anti-infectives. Its patent protection extends into 2034 to 2035, while the ENCORE results strengthen the case for broader use. The potential label expansion would increase the addressable market but also place the product in earlier-line treatment decisions.
TPIP faces the broadest competitive field. Pulmonary hypertension includes established drug classes and large pharmaceutical competitors, while pulmonary fibrosis includes several approved and pipeline treatments. TPIP's reported efficacy, dosing flexibility up to 1,280 micrograms once daily, and 91% continuation rate create a credible differentiation argument, but Phase III execution remains essential before that advantage becomes commercial.
Biotechnology funding and valuation remain sensitive to interest rates, regulatory outcomes, and reimbursement policy. Insmed reduces some financing exposure through commercial revenue, but its 2025 operating cash flow was negative $935.0M and quarterly Q2 free cash flow was negative $321.3M. The company expects cash-flow positivity in 2027, making execution against the BRINSUPRI launch especially important.
International expansion introduces both opportunity and policy risk. BRINSUPRI received U.K. authorization in February 2026, and Insmed expects a Japanese regulatory decision during 2026. The company intends to pursue Japanese submissions for expanded ARIKAYCE use, with potential launches in 2027. Management also said its peak-sales assumptions include the impact of IRA-related price negotiation beginning in 2035, showing that pricing policy is part of the long-range model.
Broader biotechnology trends support Insmed's focus on high-unmet-need diseases. MarketsandMarkets estimates the global biotechnology industry at $546.0B in 2025, while Mordor Intelligence estimates the broader market at $2.42T in 2026. These figures use different market definitions, but both identify a large, expanding industry. Insmed's narrow respiratory focus gives it a more specific commercial path than a platform biotech dependent only on future discoveries.
Cash and investments were $1.2B at quarter-end, but 2025 free cash flow was negative $967.6M, so the balance sheet still depends on BRINSUPRI’s ramp to fund the next phase.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →Second-quarter revenue reached $425.5M while operating loss narrowed to just $1.5M, showing a dramatic improvement from the $163.6M net loss in Q1.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →Management lifted 2026 BRINSUPRI revenue guidance to $1.25B-$1.4B and kept ARIKAYCE guidance at $450M-$470M, signaling confidence in the launch curve.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →At a $28.6B market cap and 25.3x enterprise value-to-revenue, INSM already prices in a lot of BRINSUPRI success despite negative trailing EPS of $4.12.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →The report’s fair value sits at $185, with upside to $230 and $280 only if BRINSUPRI sustains its pace and TPIP continues to de-risk.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →Insmed has built a credible commercial platform around two respiratory products, and the numbers now support more than a speculative biotech narrative. Q2 revenue reached $425.5M, BRINSUPRI revenue reached $309.2M, gross margin reached 84.2%, and operating loss narrowed to $1.5M. Those figures show a business approaching an important financial inflection.
The investment case still depends on a demanding sequence of events: continued BRINSUPRI prescriber expansion, successful ARIKAYCE label growth, cash-flow positivity in 2027, and positive TPIP Phase III execution. A Buy rating is justified at the current price because the commercial evidence is strong and the projected earnings curve is steep. Position sizing should remain moderate because the valuation already rewards a large share of that future success.
Get AI-powered research reports, daily market intelligence, and a personal analyst in your pocket.
Get Full Access →Not ready to subscribe? ·
Cancel anytime
Insmed Incorporated (INSM) spikes in extended-hours trading after its second-quarter 2026 earnings and business update. Investors are reacting to BRINSUPRI’s commercial momentum, analyst support, and the company’s push toward at least $1 billion in 2026 revenue.
Insmed has evolved into a commercial-stage rare respiratory company with two marketed products and a fast-scaling launch. BRINSUPRI is driving the revenue inflection, while ARIKAYCE and a late-stage pipeline add durability and upside.
Insmed Incorporated (INSM) climbs sharply as investors continue to digest its strong Q1 update, including rapid BRINSUPRI growth, steady ARIKAYCE sales, and encouraging ENCORE data. The move reflects renewed confidence in the company’s 2026 revenue targets and its expanding commercial and pipeline story.